Jian-Yong Shao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2477006/publications.pdf Version: 2024-02-01



LIAN-YONG SHAO

#	Article	IF	CITATIONS
1	Plasma SGIP1 methylation in diagnosis and prognosis prediction in hepatocellular carcinoma. Neoplasma, 2021, 68, 62-70.	1.6	5
2	The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients. Disease Markers, 2021, 2021, 1-9.	1.3	19
3	Diagnostic and Prognostic Characteristics of Circulating Free DNA Methylation Detected by the Electrochemical Method in Malignant Tumors. Cancers, 2021, 13, 664.	3.7	3
4	Performance of common genetic variants in risk prediction for colorectal cancer in Chinese: A two-stage and multicenter study. Genomics, 2021, 113, 867-873.	2.9	1
5	Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis. Clinical and Translational Medicine, 2020, 10, 353-362.	4.0	13
6	Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling. Journal of Oncology, 2020, 2020, 1-13.	1.3	8
7	Risk stratification for nasopharyngeal carcinoma: a real-world study based on locoregional extension patterns and Epstein-Barr virus DNA load. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093205.	3.2	17
8	Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma. JAMA Network Open, 2020, 3, e2029882.	5.9	31
9	Development and validation of a prognostic nomogram for the pre-treatment prediction of early metachronous metastasis in endemic nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592097813.	3.2	6
10	The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer. Genetic Testing and Molecular Biomarkers, 2019, 23, 589-597.	0.7	3
11	Prognostic Implications of Tripartite Motif Containing 24 Expression Levels in Patients with Solid Tumors: A Systematic Review and Meta-Analysis. Genetic Testing and Molecular Biomarkers, 2019, 23, 473-479.	0.7	1
12	<p>Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients</p> . Cancer Management and Research, 2019, Volume 11, 3721-3739.	1.9	15
13	Past and Recent Salted Fish and Preserved Food Intakes Are Weakly Associated with Nasopharyngeal Carcinoma Risk in Adults in Southern China. Journal of Nutrition, 2019, 149, 1596-1605.	2.9	25
14	Interfering Expression of Chimeric Transcript <i> SEPT7P2-PSPH</i> Promotes Cell Proliferation in Patients with Nasopharyngeal Carcinoma. Journal of Oncology, 2019, 2019, 1-10.	1.3	9
15	Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2019, 104, 355-361.	0.8	64
16	Prognostic implications of a molecular classifier derived from wholeâ€exome sequencing in nasopharyngeal carcinoma. Cancer Medicine, 2019, 8, 2705-2716.	2.8	13
17	Medical History, Medication Use, and Risk of Nasopharyngeal Carcinoma. American Journal of Epidemiology, 2018, 187, 2117-2125.	3.4	20
18	SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility. Gene, 2018, 640, 43-50.	2.2	19

JIAN-YONG SHAO

#	Article	IF	CITATIONS
19	Hypermethylation of APC2 Is a Predictive Epigenetic Biomarker for Chinese Colorectal Cancer. Disease Markers, 2018, 2018, 1-7.	1.3	9
20	Pretreatment quality of life as a predictor of survival for patients with nasopharyngeal carcinoma treated with IMRT. BMC Cancer, 2018, 18, 114.	2.6	13
21	The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients. Cancer Research and Treatment, 2018, 50, 19-29.	3.0	56
22	Serum micro <scp>RNA</scp> profiles as diagnostic biomarkers for <scp>HBV</scp> â€positive hepatocellular carcinoma. Liver International, 2017, 37, 888-896.	3.9	56
23	Quantification of familial risk of nasopharyngeal carcinoma in a highâ€incidence area. Cancer, 2017, 123, 2716-2725.	4.1	54
24	Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. American Journal of Epidemiology, 2017, 185, 1272-1280.	3.4	68
25	SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor. Cancer Research, 2017, 77, 579-589.	0.9	47
26	Concurrent chemoradiotherapy with or without cetuximab for stage II to IVb nasopharyngeal carcinoma: a case–control study. BMC Cancer, 2017, 17, 567.	2.6	29
27	Development of a population-based cancer case-control study in southern china. Oncotarget, 2017, 8, 87073-87085.	1.8	29
28	Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma. Oncotarget, 2017, 8, 10594-10601.	1.8	5
29	Predictors of Mastoiditis after Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma: A Dose-Volume Analysis. Journal of Cancer, 2016, 7, 276-282.	2.5	4
30	Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study. Oncotarget, 2016, 7, 29739-29748.	1.8	15
31	Oral Hygiene and Risk of Nasopharyngeal Carcinoma—A Population-Based Case–Control Study in China. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1201-1207.	2.5	46
32	With or without reirradiation in advanced local recurrent nasopharyngeal carcinoma: a case–control study. BMC Cancer, 2016, 16, 774.	2.6	17
33	Comparison of KRAS mutation status between primary tumor and metastasis in Chinese colorectal cancer patients. Medical Oncology, 2016, 33, 71.	2.5	12
34	A new prognostic histopathologic classification of nasopharyngeal carcinoma. Chinese Journal of Cancer, 2016, 35, 41.	4.9	83
35	Serum microRNA profiles as prognostic biomarkers for HBV-positive hepatocellular carcinoma. Oncotarget, 2016, 7, 45637-45648.	1.8	22
36	Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy. Oncotarget, 2016, 7, 6221-6230.	1.8	37

JIAN-YONG SHAO

#	Article	IF	CITATIONS
37	LOX expression in primary nasopharyngeal carcinoma: correlation with prognostic parameters and outcome. Oncotarget, 2016, 7, 8200-8207.	1.8	14
38	Prognostic effect of pregnancy on young female patients with nasopharyngeal carcinoma: results from a matched cohort analysis. Oncotarget, 2016, 7, 21913-21921.	1.8	4
39	Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy. Scientific Reports, 2015, 5, 16664.	3.3	34
40	Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chinese Journal of Cancer, 2015, 34, 225-34.	4.9	21
41	Clinicopathologic characteristics and therapeutic responses of Chinese patients with non-small cell lung cancer who harbor an anaplastic lymphoma kinase rearrangement. Chinese Journal of Cancer, 2015, 34, 404-12.	4.9	12
42	Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone. BMC Cancer, 2015, 15, 930.	2.6	6
43	The impact of the cumulative dose of cisplatin during concurrent chemoradiotherapy on the clinical outcomes of patients with advanced-stage nasopharyngeal carcinoma in an era of intensity-modulated radiotherapy. BMC Cancer, 2015, 15, 977.	2.6	21
44	Incidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2015, 10, e0131284.	2.5	4
45	High expression of Talin-1 is associated with poor prognosis in patients with nasopharyngeal carcinoma. BMC Cancer, 2015, 15, 332.	2.6	21
46	The Prognostic Value of Plasma Epstein-Barr Viral DNA and Tumor Response to Neoadjuvant Chemotherapy in Advanced-Stage Nasopharyngeal Carcinoma. International Journal of Radiation Oncology Biology Physics, 2015, 93, 862-869.	0.8	110
47	Comparison of the treatment outcomes of intensity-modulated radiotherapy and two-dimensional conventional radiotherapy in nasopharyngeal carcinoma patients with parapharyngeal space extension. Radiotherapy and Oncology, 2015, 116, 167-173.	0.6	14
48	Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2015, 14, 2864-2873.	4.1	80
49	The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients. PLoS ONE, 2015, 10, e0124354.	2.5	17
50	TEL2 suppresses metastasis by down-regulating SERPINE1 in nasopharyngeal carcinoma. Oncotarget, 2015, 6, 29240-29253.	1.8	39
51	<i>IDH1</i> mutation detection by droplet digital PCR in glioma. Oncotarget, 2015, 6, 39651-39660.	1.8	18
52	Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. International Journal of Clinical and Experimental Medicine, 2015, 8, 8472-84.	1.3	7
53	Comparison of Long-Term Survival and Toxicity of Cisplatin Delivered Weekly versus Every Three Weeks Concurrently with Intensity-Modulated Radiotherapy in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e110765.	2.5	31
54	MicroRNA-30a promotes invasiveness and metastasis <i>inÂvitro</i> and <i>inÂvivo</i> through epithelial–mesenchymal transition and results in poor survival of nasopharyngeal carcinoma patients. Experimental Biology and Medicine, 2014, 239, 891-898.	2.4	29

JIAN-YONG SHAO

#	Article	IF	CITATIONS
55	Knockdown of miR-214 Promotes Apoptosis and Inhibits Cell Proliferation in Nasopharyngeal Carcinoma. PLoS ONE, 2014, 9, e86149.	2.5	62
56	<i>ALK</i> gene copy number gain and its clinical significance in hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 183.	3.3	13
57	Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer, 2011, 117, 3750-3757.	4.1	134
58	Eight-Signature Classifier for Prediction of Nasopharyngeal Carcinoma Survival. Journal of Clinical Oncology, 2011, 29, 4516-4525.	1.6	131
59	MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. Rna, 2008, 14, 2348-2360.	3.5	993
60	Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer, 2004, 100, 1162-1170.	4.1	194